|
Originally published In Press as doi:10.1074/jbc.M101488200 on September 10, 2001
J. Biol. Chem., Vol. 276, Issue 45, 41803-41809, November 9, 2001
Cell Cycle-dependent Interaction of Mad2 with
Conserved Box1/2 Region of Human Granulocyte-Macrophage
Colony-stimulating Factor Receptor Common c*
Mitsuo
Takeda §,
Naoshi
Dohmae¶,
Koji
Takio¶,
Ken-ichi
Arai §, and
Sumiko
Watanabe
From the Department of Molecular and Developmental
Biology, Institute of Medical Science, § Core Research for
Evolutional Science and Technology, Japan Science and Technology
Corporation, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo
108-8639, Japan, and the ¶ Biomolecular Characterization Division,
RIKEN (Institute of Physical and Chemical Research), 2-1, Hirosawa,
Wako-shi, Saitama 351-0198, Japan
Received for publication, February 16, 2001, and in revised form, September 7, 2001
 |
ABSTRACT |
Box1 and 2 (box1/2) are conserved cytoplasmic
motifs located in the membrane proximal region of cytokine receptors,
including the human granulocyte-macrophage colony-stimulating
factor (GM-CSF) receptor common c. Deletion of box1/2 abrogated all
the examined activities of GM-CSF, and this phenomenon is explained by
the loss of binding by Jak2. To test if a molecule other than Jak2 interacting with the box1/2 region plays a role in GM-CSF receptor signal transduction, we screened for molecules interacting with the
box1/2 region by a pull-down assay using recombinant purified protein
of GST fused with the c box1/2 region and a Ba/F3 cell lysate. The
mouse homologue of Mad2 protein, which plays an important role in the M
phase of the cell cycle, was revealed to associate with the box1/2
region specifically. Peptides corresponding to the box1
sequence also bound to Mad2, and mutation of the box1 decreased the Mad2 interaction. Deletion analysis indicated that interaction with box1/2 occurred through the C-terminal portion of
Mad2. Mad2 is known to change affinity for binding partners cell cycle
dependently. Binding affinity of Mad2 to box1/2 increased in the late M
phase, suggesting the possibility that GM-CSF participates in
regulation of the M phase check point through interaction with Mad2.
 |
INTRODUCTION |
Granulocyte-macrophage colony-stimulating factor
(GM-CSF)1 is a cytokine that
stimulates the proliferation and differentiation as well as survival of
various hematopoietic cells (1). The receptor of human (h) GM-CSF
(GM-CSFR) consists of two subunits, and , both of which are
members of the cytokine receptor superfamily (2). The subunit is
specific to hGM-CSFR, whereas the subunit ( c) is shared by IL-3,
GM-CSF, and IL-5 receptors (2). GM-CSF induces tyrosine phosphorylation
of c and various cellular proteins and activates early response
genes such as c-fos, c-jun, and c-myc, as well as stimulates cell proliferation in hematopoietic cells and
fibroblasts (3). GM-CSF activates various signaling molecules, including Jak2, STAT5, mitogen-activated protein kinase cascade kinases, and phosphatidylinositol 3-kinase (2). c contains box1 and
box2 regions (box1/2), which are conserved among the cytokine receptor
superfamily, and 8 tyrosine residues located in its cytoplasmic region
(4, 5). To better comprehend signaling events involved in cell
proliferation, we and others analyzed biological activities of various
mutants of c (6-8) and found that the box1 region was essential for
all of the hGM-CSFR signals we examined. Although the box1/2 region is
essential and sufficient for cell proliferation and survival, a
tyrosine residue(s) is also required for mitogen-activated protein
kinase and c-fos promoter activation (8, 9). Because box1 is
assumed to bind Jak2, it is likely that activation of Jak2 is
sufficient and essential for hGM-CSF signals through interaction with
the box1 region of c. This notion was supported by observations that
dominant negative Jak2 suppressed all the GM-CSFR signaling and
activities we investigated (7). In addition, Jak2 knockout mice showed
defects in GM-CSF-dependent colony formation (10, 11).
The box1 region contains the proline-X-proline sequence,
which is conserved among members of the cytokine receptor superfamily (12). Mutation analysis of the motif suggested a crucial role for the
motif in a variety of receptor-mediated signalings. The G-CSF receptor
mutant in which the conserved proline-X-proline is
substituted by Ala-X-Ala can induce neither DNA synthesis
nor cell proliferation (13). The mutant growth hormone receptor failed
to induce either cell proliferation or spi-1 induction (14, 15).
Similar results were obtained in the case of gp130 and the prolactin
receptor (12, 16, 17). Although the importance of the box1 region in
various receptors has been noted, structural information about this
region has been awaited. Thus, the role and mechanism of box1 function
have remained unsolved.
We have now identified Mad2 (mitotic arrest-deficient 2) protein as a
box1/2-binding protein. Mad2 was first discovered as a gene responsible
for the mitotic checkpoint in yeast (18). The knockout of Mad2 in mice
showed that Mad2 is essential in mouse cells after embryonic day 6.5, although it is dispensable for normal cell division in yeast (19).
During mitosis, Mad2 localized at an unattached kinetochore monitors
for correct spindle-kinetochore attachment, a prerequisite for
initiation of anaphase (20). The Mad2-dependent monitoring
system, maintained until the completion of spindle attachment, prevents
anaphase initiation through Mad2-Cdc20 complex formation (21-23).
Cdc20 activates the ubiquitin ligase activity of anaphase promoting
complex (APC), after which the activated APC promotes the initiation of
anaphase. There are a variety of Mad2 binding partners, including
molecules not related to the mitotic checkpoint (24-27). Here, we
found that hGM-CSFR c acts as one of such partners of Mad2 and that
their interaction is regulated in a cell cycle-dependent manner.
 |
EXPERIMENTAL PROCEDURES |
Reagents--
Recombinant murine IL-3 (mIL-3) expressed in
silkworms, Bombyx mori, was purified as described (28).
Recombinant hGM-CSF was a gift from Schering-Plough (Madison, NJ).
Antibodies anti-hGM-CSF receptor c (S-16, C-20) and anti-GST (B-14)
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-Mad2
was from Transduction Laboratory (Lexington, KY), and
anti-phosphotyrosine (4G10) from Upstate Biotechnology Inc (Lake
Placid, NY). Peptides were synthesized by using Fmoc
(N-(9-fluorenyl)methoxycarbonyl) chemistry with a Shimadzu
PSSM-8 synthesizer (Shimadzu, Kyoto, Japan). All the peptides were
designed to have a cysteine at their N terminus for iodoacetamido-based
sulfhydryl conjugation. Each peptide was conjugated with SulfoLink
coupling gel (Pierce) according to the manufacturer's instruction.
Peptide corresponding to CAGGPPGGPQVNPIPVTDEVV served as a control.
Plasmid Construction--
The plasmids encoding GST fusion
protein were constructed by using pGEX vectors (Amersham Pharmacia
Biotech, Uppsala, Sweden). GST-box1/2 was constructed by PCR
amplification of the box1/2 region corresponding to amino acids
453-544, and termination was generated after residue 544 (aspartic
acid) by PCR mutagenesis. Sequences of primers used for introduction of
mutation were 5'-ATGTGATCAGGCTGCGCAGAAAGTG-3' and
5'-CGGAATTCTAATCTGAGGCAGCTGGAG-3'. Amplified fragments were inserted
into BclI and EcoRI sites of pGEX-3X. For
GST- , hGM-CSFR subunit was digested with CvnI and
XhoI. The resulting fragment, which contained almost the
entire region of the cytoplasmic region of the subunit, was
inserted into pBS-SK (Stratagene, La Jolla, CA) at SmaI
(blunted) and XhoI sites. Then, the fragment was isolated by
BamHI and XhoI digestion and inserted into
BamHI and XhoI sites of the pGEX-5X-1 vector.
His-tagged recombinant proteins were constructed by using the
QIAexpressionist type IV pQE vector (Qiagen, Chatsworth, CA) to contain
6 histidines at their N terminus. An XhoI site was created
immediately before the initiation codon of Mad2 by PCR mutagenesis, and
the entire region of Mad2 was isolated by cleavage at XhoI
and HindIII sites. The fragment was inserted into pQE-31 at
SalI and HindIII sites. The N terminus deletion
mutant was made by insertion of Sau3AI and SacI
fragment into pQE-31 BamHI and SacI sites. C
terminus deletion was made by deletion of the region after the
DpnI site. The DpnI site was blunted and ligated to the blunted SmaI site of the pQE-31 vector. For mammalian
expression, the fragment encoding full-length wild-type Mad2 (prepared
by XhoI and SpeI sites from pCR2.1 vector;
Invitrogen, Carlsbad, CA) was inserted into XhoI and
SpeI sites of the pKU2 vector, which contains the SR
promoter (29).
Recombinant Protein Expression and Purification--
Plasmids
encoding GST fusion proteins were introduced into BL21 cells
(Escherichia coli strain), and GST fusion protein expression was induced by adding 1 mM IPTG. The cells were lysed by
sonication, and the overexpressed protein was purified on an affinity
column packed with glutathione-Sepharose4B (Amersham Pharmacia
Biotech), according to the manufacturer's instruction.
The histidine-tagged proteins were expressed in M15 cells (E. coli strain carrying a pREP4 plasmid), and purification of the protein was done by using an Ni2+-nitrilotriacetic
acid-agarose (Qiagen, Chatsworth, CA) affinity column, according to
the manufacturer's instruction. The eluents were dialyzed against 20 mM Tris-HCl, pH 7.5, and protein concentrations were
determined by using a BCA protein assay kit (Pierce).
Cell Culture and Cell Lysate Preparation--
The mouse
IL-3-dependent, pro-B cell line Ba/F3 stably expressing
both and subunits of hGM-CSFR (Ba/F-wild) was maintained in
RPMI 1640 containing 5% fetal calf serum, 0.25 ng/ml mIL-3, 50 units/ml penicillin, and 50 µg/ml streptomycin. HeLa cells were
maintained in Dulbecco's modified Eagle's medium
supplemented with 10% fetal calf serum, 50 units/ml penicillin, and 50 µg/ml streptomycin. Whole cell lysates used for pull-down assay and immunoprecipitation were prepared by using lysis buffer (40 mM Tris-HCl, pH 7.6, 50 mM KCl, 0.25% Nonidet
P-40, 2 mM EDTA, 50 mM NaF, 20 mM
-glycerophosphate, 1 mM NaVO4, 10 mM 2-mercaptoethanol, 1 mM phenylmethylsulfonyl
fluoride, 2 µg/ml aprotinin, 1 µg/ml pepstatin A, 10 µg/ml
leupeptin). The undissolved fraction of the lysate was removed by
centrifugation (15,000 × g for 30 min). Fractionation
of HeLa cell lysates into cytoplasm and nucleus portions was done as
follows. Briefly, the cells were incubated in hypotonic buffer (10 mM Hepes, pH 7.9, 10 mM KCl, 2 mM
MgCl2, 0.1 mM EDTA, 1 mM
dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride) for
15 min. Nonidet P-40 was added to the cell suspension at a final
concentration of 0.6%. The Nonidet P-40-insoluble fraction (enriched
in nuclei) was separated by centrifugation (15,000 × g for
30 s). The pellets were washed with hypotonic buffer two times and
incubated in extraction buffer (50 mM Hepes, pH 7.9, 50 mM KCl, 300 mM NaCl, 0.1 mM EDTA, 1 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl
fluoride, 10% glycerol) for 20 min. Both Nonidet P-40-soluble and
-insoluble fractions were diluted with an excess amount of the lysis
buffer used in the pull-down assay.
Pull-down Assay and Immunoprecipitation--
The lysate
(108 cells/ml) prepared from Ba/F wild cells was incubated
overnight at 4 °C with GST fusion proteins and glutathione Sepharose. GST fusion protein and associated protein(s) were eluted with 15 mM glutathione and dialyzed against 20 mM Tris-HCl, pH 7.5. The samples were lyophilized and
dissolved in suitable buffer for further analyses.
For immunoprecipitation analysis, cell lysates (2 × 107 cells/samples) were incubated with an appropriate
antibody and protein G-Sepharose 4 FF (Amersham Pharmacia Biotech)
overnight at 4 °C. The bands were visualized by using an ECL Western
blotting detection system (Amersham Pharmacia Biotech).
For preparation of cell cycle-synchronized cell lysates, HeLa cells
were arrested at the G1/S boundary by a double-thymidine block (30). Briefly, HeLa cells were treated for 14 h with
Dulbecco's modified Eagle's medium containing 2 mM
thymidine, released for 10 h in normal medium, and then treated
again with thymidine for 14 h. There after, the cells were
released in normal medium and harvested after incubation for the times
indicated in the figures. For Ba/F3 cells, cells were depleted of mIL-3
for 12 h to become arrested in the G1 phase. hGM-CSF
(2 ng/ml) was then added, and the cells were harvested at the indicated
time points. The phase of the cell cycle was confirmed by examining DNA
contents by propidium iodide staining and flow cytometry (FACScan,
Becton Dickinson, San Jose, CA). The lysates from each time point were
prepared as described above. Protein amounts of the lysates were
quantified with a BCA protein assay kit (Pierce) to confirm equal
extraction efficiency among the samples. The lysate from each time
point was divided into two tubes, and incubated with anti- c antibody (2 µg, for Ba/F3 cells), GST-box1/2 purified protein (for HeLa cells), or anti-p55CDC antibody (2 µg). Associated proteins were precipitated either with glutathione-Sepharose beads or protein G beads
and separated by SDS-PAGE followed by Western blotting using anti-Mad2 antibody.
Electrophoresis, Blotting, Amino Acid Sequence, and Cloning of
cDNA--
Two-dimensional electrophoresis, a combination of
isoelectric focusing and SDS-PAGE, was carried out according to
O'Farrell (31). Protein spots were detected either by silver staining or Western blotting. Silver staining of the PAGE gel was done with a 2D
Silver Stain II kit (Daiichi Pure Chemicals Co. Ltd., Tokyo, Japan).
For Western blotting, proteins were transferred to a polyvinylidene
difluoride membrane (Millipore, Bedford, MA) by using a semidry type
apparatus (model BE-320; Bio-Craft Co. Ltd., Tokyo, Japan) and the
blotted membrane was incubated with appropriate antibodies.
For amino acid sequencing, two-dimensional separated gels were stained
with 0.25% Coomassie Brilliant Blue and bands of 25 and 75 kDa were
excised and treated with 0.2 µg of Achromobacter protease
I (a gift from Dr. Masaki, Ibaraki University (Ref. 32)) at 37 °C
for 12 h in 0.1 M Tris-HCl, pH 9.0, containing 0.1%
SDS. The peptides generated were extracted from the gel and separated on columns of DEAE-5PW (2 × 20 mm; Tosoh, Tokyo, Japan) and
Mightysil RP-18 (2 × 50 mm; Kanto Chemical, Tokyo, Japan)
connected in series with a model 1100 (Hewlett Packard, Palo Alto, CA)
liquid chromatography system. Peptides were eluted at a flow rate of
0.1 ml/min, with a linear gradient of 0-60% solvent B, where solvents
A and B were 0.09% (v/v) aqueous trifluoroacetic acid and 0.075%
(v/v) trifluoroacetic acid in 80% (v/v) acetonitrile, respectively.
Selected peptides were subjected to Edman degradation in a model 477A
automated protein sequencer (PerkinElmer Life Sciences) connected
on-line to a model 120A PTH analyzer (PerkinElmer Life Sciences) and
also examined by matrix-assisted laser desorption ionization time of flight mass spectrometry with a Reflex MALDI-TOF (Bruker-Franzen Analytik, Bremen, Germany) in linear mode, with 2-mercaptobenzothiazole used as a matrix. For cloning of full-length mouse Mad2 cDNA, PCR
primers were designed according to the GenBankTM mouse Mad2 equivalent
sequence of expressed sequence tag. PCR fragments were recovered by
used of a TA vector (pCR2.1, Invitrogen, Carlsbad, CA), and the
sequence was confirmed by using an ABI PRISM 310 sequencer (PerkinElmer
Life Sciences).
 |
RESULTS |
Isolation of Box1/2-interacting Proteins by Pull-down
Analysis--
To determine whether proteins other than Jak2 bind to
the box1/2 region, we conducted pull-down assays using the recombinant box1/2 region of c and Ba/F3 cell lysates. GST protein fused with
the c box1/2 region (GST-box1/2) or the cytoplasmic region of subunit (GST- ) were constructed, as shown in Fig.
1A. GST-box1/2, GST- , and
GST protein were purified by using a glutathione column and then
incubated with the Ba/F3 cell lysate. Proteins were precipitated by
glutathione-Sepharose 4B beads and analyzed by two-dimensional electrophoresis. To identify GST protein-binding proteins derived from
E. coli, purified GST-box1/2, GST- fusion
proteins, and GST protein were also subjected to two-dimensional
electrophoresis, and all the gels were silver-stained. We then compared
the six panels precisely and found two proteins that specifically bound to GST-box1/2. Fig. 1B shows the pattern of
GST-box1/2-binding proteins, and arrows indicate specific
binding proteins with approximate molecular masses of 25 and 75 kDa.
The 25-kDa protein was not detected in samples prepared with GST or
GST- , and only a residual amount of the 75-kDa one co-precipitated
with GST or GST- . Because these proteins were not observed in the
gel with GST-box1/2 protein alone, these were probably specific binding
proteins that had originated from Ba/F3 cells. We excised these spots
and subjected them to microsequencing. The amino acid sequence revealed
that two fragments derived from the 75-kDa protein were contained in GRP78 protein (33). Because GRP78 exclusively localizes in the endoplasmic reticulum and its structure is closely related to Hsp-70
(33), we speculate that the binding of GRP78 to GM-CSFR is an
artificial event only observed in an in vitro system. A fragment derived from the 25-kDa protein corresponded to amino acids
193-199 of the human Mad2 protein. As the 25-kDa spot was recognized
by an anti-Mad2 antibody in two-dimensional Western blotting analysis
(data not shown), this 25-kDa protein is probably the mouse counterpart
of the human Mad2. We also analyzed the immunoreactivity of the
anti-Mad2 antibody toward GST protein-precipitated proteins by SDS-PAGE
followed by Western blotting. The anti-Mad2 antibody recognized a band
with a molecular mass of 25 kDa, and this band was observed only with
the GST-box1/2 samples incubated with the Ba/F3 cell lysate (Fig.
1C, lane 7).

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 1.
Pull-down assay of Ba/F3 cell lysates and GST
proteins fused with hGM-CSF receptor. A, schematic
representation of GST- and GST-box1/2, which contain GST portion
fused with cytoplasmic region of hGM-CSFR subunit and box1/2 region
of c, respectively. AH is the conserved homology
region. TM, transmembrane. B, silver
staining pattern after two-dimensional gel electrophoresis of
GST-box1/2-binding proteins. Pull-down assay was done by using
GST-box1/2, GST- , or GST itself, and co-precipitated proteins were
separated by two-dimensional electrophoresis. Purified GST proteins
themselves were also applied to two-dimensional electrophoresis. A
total of six panels were carefully compared, and two proteins that
bound to the GST-box1/2 specifically were identified. Panel shows the
pattern of proteins binding to GST-box1/2, and specific proteins are
indicated by the arrows. IEF, isoelectric
focusing. C, Western blotting pattern of GST protein-binding
proteins. GST-box1/2, GST- , or GST itself was incubated with or
without Ba/F3 cells lysate, and proteins precipitated with GSH beads
were separated by SDS-PAGE. Proteins were transferred to a
polyvinylidene difluoride membrane, and Western blotting was done with
anti-Mad2 antibody. D, co-immunoprecipitation of Mad2 and
hGM-CSFR c. Immunoprecipitation (IP) was done by using
Ba/F3 cell lysate with anti- c or control IgG and was followed by
Western blotting. The blotted protein was detected with anti-Mad2
antibody. The arrow indicates Mad2 detected with anti-Mad2
antibody.
|
|
To determine whether the endogenous full-length c protein binds to
Mad2, we carried out co-immunoprecipitation analysis, using anti- c
antibody (specific for human c) and Ba/F3 cells expressing hGM-CSFR.
As shown in Fig. 1D, Mad2 protein co-immunoprecipitated with
c, thereby suggesting an association of Mads with the native receptor.
We next asked whether this association is direct, and for this we used
a binding assay of recombinant Mad2 and box1/2 proteins. Full-length
mouse Mad2 coding region cDNA was isolated by PCR using
synthesizing primers according to GenBankTM mouse Mad2 equivalent sequences. The recently published sequence of the mouse Mad2 (19) completely matched the sequence of our PCR product. To obtain purified
Mad2 for the binding assay, we constructed histidine-tagged Mad2
protein (His-Mad2) and purified it. Then, binding activity of His-Mad2
protein and GST-box1/2, GST- , or GST proteins was examined. As shown
in Fig. 2 (lanes 1-3), when
the protein complex was precipitated with glutathione-Sepharose 4B
beads, only the GST-box1/2 co-precipitated with His-Mad2. Likewise,
when proteins were precipitated by Ni2+ beads, again only
the GST-box1/2 co-precipitated with the His-Mad2 protein (lanes
10-12). In contrast, neither GST- nor GST was precipitated
together with His-Mad2. Lanes 4-6 and 7-9
indicate that nearly the same amount of proteins precipitated in each
lane. These results indicate that Mad2 association with box1/2 is
specific and direct.

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 2.
Binding analysis of interaction between
recombinant purified His-Mad2 and GST-box1/2 proteins. Purified
recombinant histidine-tagged Mad2 (His-Mad2) was incubated either with
GST-box1/2, GST- , or GST itself, and proteins were precipitated with
glutathione-Sepharose 4B beads (lanes 1-3 and
7-9) or Ni2+-nitrilotriacetic acid-agarose
beads (lanes 4-6 and 10-12). The precipitated
proteins were separated through an acrylamide gel, and Western blotting
was done with anti-Mad2 antibody (lanes 1-6) or anti-GST
antibody (lanes 7-12).
|
|
Amino Acid Sequence of Box1/2 Required for Mad2 Binding--
We
next examined the requirement of the box1/2 sub-region for binding to
Mad2 protein, using a c-derived peptide conjugated with SulfoLink
beads. Various peptides corresponding to a portion of the box1/2 region
or its derivatives were synthesized and conjugated with SulfoLink beads
at their N-terminal cysteine residue (Fig. 3A). The association with Mad2
was examined by incubating these peptides with Ba/F3 cell lysate, and
the proteins that bound to the peptide beads were precipitated and
separated by SDS-PAGE. Fig. 3B shows the Western blotting
pattern obtained by using anti-Mad2 antibody for reaction with the
precipitated proteins. Mad2 co-precipitated with the peptide-beads that
covered the entire box1 region (lane 2). We next examined
the binding potential of various box1/2-derived peptides. Neither box2
peptide nor control peptide precipitated Mad2 protein (lanes
4 and 7). Amino acids "PNP" conserved within box1
region of many cytokine receptors are thought to be critical for signal
transduction as determined by mutation analysis of several receptors
(12). When a peptide carrying a mutation within this conserved PNP
motif (box1/ANA) was used for precipitation, the amount of
co-precipitated Mad2 was significantly reduced (lane 3). It
was also reported that 8 amino acid residues are critical for receptor
activation (7, 34). The box1 peptide, which lacks these critical
residues ( Box1), abrogated Mad2 precipitation (lane 6).
The peptide corresponds to a joint region of box1 and box2 also could
not precipitate Mad2 (lane 5). These results suggest that
the conserved region of box1 plays an important role in binding to Mad2
protein. We also checked direct binding between recombinant purified
His-Mad2 and these peptides, and essentially the same results (data not
shown) as obtained with the Ba/F3 cell lysate emerged.

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 3.
Analysis of the requirement of a region of
box1/2 for binding with Mad2 by use of peptides corresponding to the
box1/2 sequence. A, peptides corresponding to the
box1/2 region are schematically shown. B, the peptides
conjugated with SulfoLink coupling gel were mixed with Ba/F3 cell
lysates and precipitated. Precipitates were separated through
acrylamide gel, and Western blotting was done with anti-Mad2
antibody.
|
|
Region of Mad2 Required for Binding to c--
To analyze the
region of Mad2 required for binding to c, we next constructed
deletion mutants of Mad2, as schematically shown in Fig.
4A. Mutants were fused at
their N terminus with a histidine tag for purification. Purified
histidine-tagged Mad2 mutant proteins were incubated with purified GST
box1/2, and the proteins were precipitated using glutathione-Sepharose
4B beads and analyzed by Coomassie Brilliant Blue staining (Fig.
4B). The GST-box1/2 could bind wild type (lane 2)
as well as mutant Mad2 lacking the N-terminal portion ( N, lane
4), but the amount of precipitated N-Mad2 was clearly less than
that of the wild-type Mad2, thus indicating that the N-terminal region
of Mad2 was not essential for but influenced the binding affinity
between Mad2 and box1/2. In contrast, mutant Mad2 lacking the C
terminus ( C) did not bind to GST-box1/2 (lane 3). In view
of these data, we speculate that the C-terminal portion (54 residues,
amino acid positions 152-205) is sufficient and is required to
interact with GST-box1/2. The anti-Mad2 antibody, which recognizes the
N mutant but not the C mutant interfered with the association
between box1/2 protein and Mad2 of Ba/F3 lysates, in a
dose-dependent manner (Fig. 4C). In contrast, control
antibodies, anti- -catenin, and anti-phosphotyrosine (4G10), did not
affect Mad2 binding, thereby supporting the conclusion that the
C-terminal region of Mad2 is important and sufficient for binding
between box1/2 and Mad2.

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 4.
Region of Mad2 required for binding to
box1/2. A, mutants of Mad2 lacking either the
C-terminal or N-terminal portion were constructed. The mutants and wild
type contained a histidine tag at their N terminus. B,
binding of mutants of Mad2 to purified GST-box1/2. Purified recombinant
mutant His-Mad2 proteins were incubated with purified GST-box1/2, and
the proteins were co-precipitated by using glutathione-Sepharose 4B
beads and analyzed by SDS-PAGE followed by Coomassie Brilliant Blue
staining. C, effect of addition of anti-Mad2 antibody to the
association between GST-box1/2 and Mad2. Ba/F3 lysate was incubated
with GST-box1/2 in the presence of various amounts of anti-Mad2
antibody or control antibody. Proteins were co-precipitated and
analyzed by Western blotting.
|
|
Cell Cycle-dependent Binding of Mad2 to Box1/2 of
c--
Mad2 associates with various cell cycle-related proteins in
a cell cycle phase-dependent manner (21, 22, 30, 35, 36). To determine whether the association between Mad2 and c is also affected during the cell cycle, we prepared HeLa cell lysates at
various phases of the cell cycle. HeLa cells were arrested at
G1 by a thymidine double block and released from arrest by removing thymidine. Cells were harvested at the time points indicated in Fig. 5A, and a portion was
used to analyze the cell cycle. Cell lysates prepared from harvested
cells were divided to two samples. With one being incubated with
GST-box1/2 protein and precipitated with glutathione-Sepharose 4B
beads. And the other immunoprecipitated with anti-p55 CDC (Cdc20)
antibody. The co-precipitated Mad2 was then analyzed by Western
blotting (Fig. 5A). As expected, association between Mad2
and p55CDC was not observed at the G1/S phase but became
slightly visible 6 h after release from the thymidine block and
was dramatically enhanced with a peak at 9 h, as reported (30). At
that time, the total amount of Mad2 found in the total lysate
(bottom panel) had increased between 6 and 9 h and then continued to increase gradually along with cell cycle
progression. A low level of association between Mad2 and box1/2 was
observed 9 h after the release from the thymidine block. In
contrast to the finding that the association of p55CDC and Mad2 was
transient, the extent of association between Mad2 and box1/2 increased
for at least 15 h. These results suggest that p55CDC and box1/2
may associate with Mad2 through different mechanisms. In addition, when
GST-box1/2-precipitated membrane was blotted with anti-p55CDC, no band
was observed, which meant that a triple complex of Mad2, p55CDC, and
c may not have formed. Using fractionated cell lysates, we next
examined whether or not the changes in the binding pattern were caused
by a change in the subcellular localization of Mad2. The assay of
GST-box1/2 and Mad2 binding was done as described in Fig. 5A
except that fractionated HeLa cell lysates were used. HeLa cell lysates
were divided into 0.6% Nonidet P-40 soluble fraction (cytoplasmic
portion) and high salt-extracted fraction (nuclear fraction), and the
binding assay using recombinant purified GST-box1/2 was done. The total
amount of Mad2 in the fractions was analyzed by Western blotting. As
shown in Fig. 5B, binding of Mad2 with GST-box1/2 was seen
only with the cytoplasmic fraction. The time course of binding was
similar to that observed for the total cell extract. In contrast, no
visible binding was observed with Mad2 from the nuclear fraction,
although there was a greater amount of Mad2 in this fraction. These
results indicate that the change in the binding property between box1/2
and Mad2 may be regulated by a change in affinity, not by a change in
subcellular localization. Using Ba/F3 cells, we next examined the
binding property of Mad2 in various phases of cell cycle progression. Ba/F3 cells were depleted of mIL-3 for 12 h and then re-stimulated with hGM-CSF. At selected time points, cell cycle progression was
analyzed by using propidium iodide (Fig. 5C), and Mad2
binding affinity for c or p55CDC was examined as done when HeLa
cells were used. Intensities of bands were calculated, and relative values are presented (Fig. 5D). Binding patterns between
Mad2 and p55CDC or c obtained with Ba/F3 cells were similar to those observed with HeLa cells.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 5.
Cell cycle-dependent association
of Mad2 with box1/box2 region. A, HeLa cells were
G1-arrested by using thymidine and released from the block
by removing the thymidine. The whole cell lysates obtained at the indicated time points were divided to two
portions, and proteins of both samples were precipitated either with
anti-p55CDC antibody (upper panel) or GST-box1/2
(middle panel), and the co-precipitated Mad2 was
analyzed by Western blotting. The amount of Mad2 in the total cell
lysate was analyzed by Western blotting using anti-Mad2 antibody
(bottom panel). IP,
immunoprecipitation. In B, essentially the same experiments
as in A were done except that HeLa cell lysates were
fractionated into cytoplasm and nuclear portions. Then, both fractions
were precipitated with GST-box1/2, and a part of each was subjected to
Western blotting using anti-Mad2 antibody to examine the total amount
of Mad2. C and D, Ba/F3 cells were depleted of
mIL-3 and then re-stimulated by hGM-CSF. Cells were collected at the
indicated time points, and immunoprecipitation using anti-p55CDC ( )
or - c ( ) antibodies or cell cycle analysis (C) were
done. The intensity of co-immunoprecipitated Mad2 bands is also
presented (D).
|
|
 |
DISCUSSION |
Here, we identified Mad2 as a molecule interacting with the box1/2
region of hGM-CSFR c. Interaction of Mad2 with membrane protein was
reported previously for the insulin receptor, where the C-terminal 30 amino acids of the insulin receptor was required for this interaction
(27), and this region contained a sequence similar to the common motif
observed in the box1 region of cytokine receptors (12). Because peptide
analysis showed the importance of the conserved amino acid motif of the
c box1 region for Mad2 binding, a similar motif may also play a role
in the binding between Mad2 and the insulin receptor. The insulin
receptor activates Jak1 and Jak2 (37), but the region of this receptor
responsible for binding to Jak proteins has not yet been revealed.
Because Jak2 is assumed to interact with the box1/2 region of cytokine receptors, it thus can be speculated that Jak proteins bind to the
insulin receptor through the same region as Mad2. Mad2 dissociates from
insulin receptor by insulin stimulation (27). We examined the effects
of hGM-CSF stimulation on Mad2 binding with c, but no clear change
of Mad2 and c binding state up to 10 h after hGM-CSF
stimulation was observed (data not shown). However, Mad2/ c association was increased after 12 h of hGM-CSF stimulation with the cell cycle progression. The addition of insulin induces tyrosine phosphorylation of the insulin receptor, and a C-terminal
phosphorylated tyrosine residue is assumed to decrease binding affinity
for Mad2 (27). In the case of c, the absence of a tyrosine residue
in the box1/2 region may be a possible reason for the lack of effect of
hGM-CSF for Mad2 and c binding in the early phase after stimulation.
The C terminus of Mad2 appeared to be important for binding with c.
Previous studies showed the importance of the Mad2 C terminus for
binding with other Mad2 partners such as Cdc20 and Mad1 in mammalian
and yeast systems (38, 39). The Mad2 contains the HORMA (for
Hop1p, Rev7p, and Mad2) domain
(40), which was found by comparative analysis of Mad2 and other
proteins. We found that a part of the HORMA domain of Mad2 C terminus
contained a motif of the TPR (tetratrico peptide repeat) domain (41),
which is known to play an important role in protein-protein
interaction. The TPR-like motif is found only within Mad2 among other
HORMA domain proteins, thus indicating the possibility that the unique feature of Mad2 interaction with other proteins can be explained by the
combinational effects of TPR and HORMA domains.
Mad2 is known to change its affinity toward interacting molecules
during cell cycle progression (35). Interestingly, the affinity of Mad2
for the box1/2 region also changed during cell cycle progression in
both Ba/F3 and HeLa cells. We found that the C terminus of Mad2 was
important for binding with c. Because one of the Mad2 M phase
binding partners, p55CDC (Cdc20), binds to the C terminus of Mad2 (39),
c and p55CDC may use a similar mechanism to bind to Mad2. When we
examined the time course of the Mad2/ c association precisely, the
binding became visible slightly later than that of Mad2/p55CDC protein
in both HeLa and Ba/F3 cells, suggesting that additional mechanisms may
differently regulate the affinity of c and p55CDC for Mad2. We found
that Mad2 recovered in the 0.6% Nonidet P-40-soluble fraction bound to
GST-box1/2 but that no binding occurred with the fraction extracted by
the high salt condition, suggesting that the change in binding property
is mainly caused by a change in affinity rather than one in subcellular
localization. The trigger and mechanism of its changing of binding
affinity of Mad2 to other partner proteins has not been clarified. We
speculate that Mad2 may be modified in response to hGM-CSF stimulation,
because GM-CSF activates cascades of kinases. Indeed, at the C terminus
region of Mad2, there are several potential phosphorylation sites, but
no report has appeared to suggest phosphorylation of the Mad2. To
examine posttranslational modification of Mad2, we extensively examined
mobility profile of Mad2 by two-dimensional gel electrophoresis, but
Mad2 prepared from different phases of the cell cycle had the same
mobility profile (data not shown). Further examination of tyrosine
phosphorylation by Western blotting showed no detectable tyrosine
phosphorylation. Taken together, our data indicate
that some other mechanism(s) than phosphorylation is probable for the
modification of Mad2.
Mad2 plays a major role in the nucleus as a member of the APC complex,
and changing of the subcellular localization of Mad2 during cell cycle
progression was reported. Mad2 appeared within the kinetochore in the
G2/M phase but disappeared after cytokinesis (42). We also
observed immunohistochemically a similar pattern of the subcellular
localization of Mad2 overexpressed in Ba/F3 cells (data not shown). We
hypothesize that the cytokine receptor anchors Mad2 in the cytoplasm
until the appropriate time and that after its release, Mad2 is
translocated to the nucleus where it functions as a member of the M
phase checkpoint. Because the binding affinity between Mad2 and c
gradually increased after M phase, it is feasible that the cytokine
receptor captures Mad2 after completion of spindle formation and keeps
it until the appropriate time. As cytokine receptors are known to be
internalized after ligand binding, the possibility exists that
internalized GM-CSFR meets Mad2 in the cytoplasm.
The primary role of the c-box1/2 is thought to be interaction with
Jak2, and Jak2 is responsible for all of the examined activities of
GM-CSF (7). We examined whether the bindings of Jak2 and Mad2 to c
compete with each other or not, but obtained no clear biochemical
result. We examined the effects of overexpressed Mad2 on
GM-CSF-dependent cell proliferation, but neither
augmentation nor suppression was observed (data not shown).
Furthermore, overexpression of Mad2 had no effect on GM-CSF-induced
c-fos- or E2F target site promoter activation. Because all
of these activities require Jak2 activation (7), Mad2 may not interfere
with the binding of Jak2 to c in vivo.
The point of the cell cycle regulated by growth factors is assumed
to be mainly in the G1/S phase transition. For example, the
Ba/F3 cell line, which was used in this present study, is mIL-3-dependent, and classical experiments using transient
stimulation of Ba/F3 cells indicate that the presence of cytokine only
at the G1/S phase can promote completion of the whole cell
cycle (data not shown). Most assays are employed to analyze signals and
functions of growth factors that are early events after growth factor
stimulation. Thus, although the regulation of biochemical events in the
G1/S transition have been extensively studied, the regulation of the G2/M phase by growth factors has received
less attention. How does the cytokine receptor contribute to M phase progression? Our results suggest new mechanism of regulation of the
cell cycle by cytokine in the M phase.
 |
ACKNOWLEDGEMENTS |
We are grateful for Drs. T. Itoh, A. Muto,
and Y. Sakurai for discussion and Y. Aoki and Y. Izawa for technical assistance.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of
Molecular and Developmental Biology, Inst. of Medical Science,
University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan. Tel.: 81-3-5449-5660; Fax: 81-3-5449-5424; E-mail:
sumiko@ims.u-tokyo.ac.jp.
Published, JBC Papers in Press, September 10, 2001, DOI 10.1074/jbc.M101488200
 |
ABBREVIATIONS |
The abbreviations used are:
GM-CSF, granulocyte-macrophage colony-stimulating factor;
hGM-CSF, human granulocyte-macrophage colony-stimulating factor;
GM-CSFR, granulocyte-macrophage colony-stimulating factor receptor;
IL, interleukin;
APC, anaphase promoting complex;
GST, glutathione
S-transferase;
PCR, polymerase chain reaction;
PAGE, polyacrylamide gel electrophoresis;
TPR, tetratrico peptide repeat;
HORMA, Hop1p, Rev7p, and
Mad2.
 |
REFERENCES |
| 1.
|
Arai, K.,
Lee, F.,
Miyajima, A.,
Miyatake, S.,
Arai, N.,
and Yokota, T.
(1990)
Annu. Rev. Biochem.
59,
783-836[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Miyajima, A.,
Mui, A. L.-F.,
Ogorochi, T.,
and Sakamaki, K.
(1993)
Blood
82,
1960-1974[Free Full Text]
|
| 3.
|
Watanabe, S.,
Mui, A. L.-F.,
Muto, A.,
Chen, J. X.,
Hayashida, K.,
Miyajima, A.,
and Arai, K.
(1993)
Mol. Cell. Biol.
13,
1440-1448[Abstract/Free Full Text]
|
| 4.
|
Hayashida, K.,
Kitamura, T.,
Gorman, D. M.,
Arai, K.,
Yokota, T.,
and Miyajima, A.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
9655-9659[Abstract/Free Full Text]
|
| 5.
|
Murakami, M.,
Hibi, M.,
Nakagawa, N.,
Nakagawa, T.,
Yasukawa, K.,
Yamanishi, K.,
Taga, T.,
and Kishimoto, T.
(1993)
Science
260,
1808-1810[Abstract/Free Full Text]
|
| 6.
|
Sakamaki, K.,
Miyajima, I.,
Kitamura, T.,
and Miyajima, A.
(1992)
EMBO J.
11,
3541-3550[Medline]
[Order article via Infotrieve]
|
| 7.
|
Watanabe, S.,
Itoh, T.,
and Arai, K.
(1996)
J. Biol. Chem.
271,
12681-12686[Abstract/Free Full Text]
|
| 8.
|
Okuda, K.,
and Griffin, J.
(1997)
Blood
90,
4759-4760[Abstract/Free Full Text]
|
| 9.
|
Itoh, T.,
Liu, R.,
Yokota, T.,
Arai, K.,
and Watanabe, S.
(1998)
Mol. Cell. Biol.
18,
742-752[Abstract/Free Full Text]
|
| 10.
|
Neubauer, H.,
Cumano, A.,
Muller, M.,
Wu, H.,
Huffstadt, U.,
and Pfeffer, K.
(1998)
Cell
93,
397-409[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Parganas, E.,
Wang, D.,
Stravopodis, D.,
Topham, D. J.,
Marine, J.-C.,
Teglund, S.,
Vanin, E. F.,
Bodner, S.,
Colamonici, O. R.,
van Deursen, J. M.,
Grosveld, G.,
and Ihle, J. N.
(1998)
Cell
93,
385-395[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Murakami, M.,
Narazali, M.,
Hibi, M.,
Yawata, H.,
Yasukawa, K.,
Hamaguchi, M.,
Taga, T.,
and Kishimoto, T.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
11349-11353[Abstract/Free Full Text]
|
| 13.
|
Avalos, B. R.,
Hunter, M. G.,
Parker, J. M.,
Ceselski, S. K.,
Druker, B. J.,
Corey, S. J.,
and Mehta, V. B.
(1995)
Blood
85,
3117-3126[Abstract/Free Full Text]
|
| 14.
|
Dinerstein, H.,
Lago, F.,
Goujon, L.,
Ferrag, F.,
Esposito, N.,
Finidori, J.,
Kelly, P. A.,
and Postel-Vinay, M. C.
(1995)
Mol. Endocrinol.
9,
1701-1707[Abstract/Free Full Text]
|
| 15.
|
Wang, Y. D.,
and Wood, W. I.
(1995)
Mol. Endocrinol.
9,
303-311[Abstract/Free Full Text]
|
| 16.
|
O'Neal, K. D.,
and Shearer, W. T.
(1995)
Mol. Cell. Biol.
15,
4657-4658[Medline]
[Order article via Infotrieve]
|
| 17.
|
O'Neal, K. D., Yu-,
Lee, L. Y.,
and Shearer, W. T.
(1995)
Ann. N. Y. Acad. Sci.
766,
282-284[Medline]
[Order article via Infotrieve]
|
| 18.
|
Li, R.,
and Murray, A. W.
(1991)
Cell
66,
519-531[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Dobles, M.,
Liberal, V.,
Scott, M. L.,
Benezra, R.,
and Sorger, P. K.
(2000)
Cell
101,
635-645[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Pennisi, E.
(1998)
Science
279,
477-478[Free Full Text]
|
| 21.
|
Fang, G., Yu, H.,
and Kirschner, M. W.
(1998)
Genes Dev.
12,
1871-1883[Abstract/Free Full Text]
|
| 22.
|
Hwang, L. H.,
Lau, L. F.,
Smith, D. L.,
Mistrot, C. A.,
Hardwick, K. G.,
Hwang, E. S.,
Amon, A.,
and Murray, A. W.
(1998)
Science
279,
1041-1044[Abstract/Free Full Text]
|
| 23.
|
Elledge, S. J.
(1998)
Science
279,
999-1000[Free Full Text]
|
| 24.
|
Liu, Y. C.,
Pan, J.,
Zhang, C.,
Fan, W.,
Collinge, M.,
Bender, J. R.,
and Weissman, S. M.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
4313-4318[Abstract/Free Full Text]
|
| 25.
|
Poelzl, G.,
Kasai, Y.,
Mochizuki, N.,
Shaul, P. W.,
Brown, M.,
and Mendelsohn, M. E.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
2836-2839[Abstract/Free Full Text]
|
| 26.
|
Nelson, K. K.,
Schlondorff, J.,
and Blobel, C. P.
(1999)
Biochem. J.
343,
673-680
|
| 27.
|
O'Neill, T. J.,
Zhu, Y.,
and Gustafson, T. A.
(1997)
J. Biol. Chem.
272,
10035-10040[Abstract/Free Full Text]
|
| 28.
|
Miyajima, A.,
Schreurs, J.,
Otsu, K.,
Kondo, A.,
Arai, K.,
and Maeda, S.
(1987)
Gene (Amst.)
58,
273-281[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Takebe, Y.,
Seiki, M.,
Fujisawa, J.,
Hoy, P.,
Yokota, K.,
Arai, K.,
Yoshida, M.,
and Arai, N.
(1988)
Mol. Cell. Biol.
8,
466-472[Abstract/Free Full Text]
|
| 30.
|
Wassmann, K.,
and Benezra, R.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
11193-11198[Abstract/Free Full Text]
|
| 31.
|
O'Farrell, P. H.
(1975)
J. Biol. Chem.
250,
4007-4021[Abstract/Free Full Text]
|
| 32.
|
Masaki, T.,
Tanabe, M.,
Nakamura, K.,
and Soejima, M.
(1981)
Biochim. Biophys. Acta
660,
44-50[Medline]
[Order article via Infotrieve]
|
| 33.
|
Munro, S.,
and Pelham, H. R. B.
(1986)
Cell
46,
291-300[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Quelle, F. W.,
Sato, N.,
Witthuhn, B. A.,
Inhorn, R. C.,
Eder, M.,
Miyajima, A.,
Griffin, J.,
and Ihle, J. N.
(1994)
Mol. Cell. Biol.
14,
4335-4341[Abstract/Free Full Text]
|
| 35.
|
Li, Y.,
Gorbea, C.,
Mahaffey, D.,
Rechsteiner, M.,
and Benezra, R.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
12431-12436[Abstract/Free Full Text]
|
| 36.
|
Kallio, M.,
Weinstein, J.,
Daum, J. R.,
Burke, D. J.,
and Gorbsky, G. J.
(1998)
J. Cell Biol.
141,
1393-1406[Abstract/Free Full Text]
|
| 37.
|
Gual, P.,
Baron, V.,
Lequoy, V.,
and Van Obberghen, E.
(1998)
Endocrinology
139,
884-893[Abstract/Free Full Text]
|
| 38.
|
Chen, R. H.,
Brady, D. M.,
Smith, D.,
Murray, A. W.,
and Hardwick, K. G.
(1999)
Mol. Biol. Cell
10,
2607-2618[Abstract/Free Full Text]
|
| 39.
|
Luo, X.,
Fang, G.,
Coldiron, M.,
Lin, Y., Yu, H.,
Kirschner, M. W.,
and Wagner, G.
(2000)
Nat. Struct. Biol.
7,
224-229[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Aravind, L.,
and Koonin, E. V.
(1998)
Trends Biochem. Sci.
23,
284-286[Medline]
[Order article via Infotrieve]
|
| 41.
|
Lamb, J. R.,
Tugendreich, S.,
and Hieter, P.
(1995)
Trends Biochem. Sci.
20,
257-259[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Li, Y.,
and Benezra, R.
(1996)
Science
274,
246-248[Abstract/Free Full Text]
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Ito, C. R. Mantel, M.-K. Han, S. Basu, S. Fukuda, S. Cooper, and H. E. Broxmeyer
Mad2 is required for optimal hematopoiesis: Mad2 associates with c-Kit in MO7e cells
Blood,
March 1, 2007;
109(5):
1923 - 1930.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Aoki, N. Suzui, S. Fujimaki, N. Dohmae, K. Yonekura-Sakakibara, T. Fujiwara, H. Hayashi, T. Yamaya, and H. Sakakibara
Destination-Selective Long-Distance Movement of Phloem Proteins
PLANT CELL,
June 1, 2005;
17(6):
1801 - 1814.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Pati, B. R. Haddad, A. Haegele, H. Thompson, F. S. Kittrell, A. Shepard, C. Montagna, N. Zhang, G. Ge, S. K. Otta, et al.
Hormone-Induced Chromosomal Instability in p53-Null Mammary Epithelium
Cancer Res.,
August 15, 2004;
64(16):
5608 - 5616.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Umezu-Goto, Y. Kishi, A. Taira, K. Hama, N. Dohmae, K. Takio, T. Yamori, G. B. Mills, K. Inoue, J. Aoki, et al.
Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production
J. Cell Biol.,
July 22, 2002;
158(2):
227 - 233.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|